Case reports
2
), and thiotepa patients receiving autotransplants who developed NMS.
(total dose 500 mg/m 2 ) with an autologous stem cell transWith the common use of neuroleptic and other related plant as previously described. 7 At the time of transplanpsychotropic medications in the peri-transplant period tation the neurologic examination and cerebrospinal fluid and the associated physiologic stress of the procedure, (CSF) were normal. On day +2, he became anxious and we believe that NMS may be unrecognized and account agitated, and developed insomnia. Lorazepam (1-2 mg i.v. for significant morbidity in this setting.
every 6-8 h) and haloperidol (2-5 mg i.v. every 6 h) were Keywords: neuroleptic malignant syndrome; autotransstarted. Within 48 h he became febrile (40°C) and plant developed mucositis and pancytopenia. Ceftazidime was begun followed later by amphotericin for persistent fever. On day +6, he developed disorientation, hallucinations, tremors, and increasing agitation. CSF and a CT-head were Neuroleptic malignant syndrome (NMS) is a rare disorder normal. Haloperidol was increased to 5 mg, i.v. every 4 h, characterized by hyperthermia, elevated creatine phosphofor better symptom control. Granulocytes rose to kinase, extrapyramidal effects, autonomic instability, alt-Ͼ0.5 × 10 9 /l on day +9, however, fever continued and he ered level of consciousness and leukocytosis.
1 NMS was developed marked generalized rigidity, supraventricular described in 1968, 2 yet there are no standard diagnostic critachycardia, labile blood pressure, incontinence, rhabdoteria. 3 The reported incidence is 0.1-12.2% in patients myolysis (CPK 653 U/l, nl Ͻ190), and acute renal failure receiving neuroleptic and related medications. 4 NMS is (creatinine, 2.3 mg/dl). Haloperidol was discontinued on extensively described in the neuropsychiatric literature, 5 day +10, and within the next 5 days, mental status norusually in association with neuroleptic medication but also malized, and the fever, rigidity and tremors resolved, with in patients receiving antiemetics and following perioper-CPK and creatinine returning to normal levels. ative sedation. 6 There are no reports of NMS after transplantation. We describe two patients who developed feaCase 2 tures of NMS within 10 days of an autotransplant, and who improved rapidly after stopping the neuroleptic drugs.
A 46-year-old woman with stage IIIB, inflammatory breast carcinoma received three cycles of chemotherapy followed by a modified radical mastectomy with axillary lymph node dissection. She next received high-dose chemotherapy and stem cell autotransplant as described for case 1. She developed nausea and vomiting and received prochlorperazine (10 mg i.v. every 6 h) and droperidol (2.5 mg i.v. every 4 h). On day +4, she developed neutropenia and a fever of the patient became confused, incontinent, restless and tation, stupor (case 1) and episodic agitation. Mutism, catatonia, and coma are also reported. 6, 8, 11 mildly agitated, and on day +10, developed fevers to 41°C, labile blood pressure, tachycardia, rhabdomyolysis (CPK Organic brain syndrome, exhaustion, dehydration, and concurrent medical illnesses are considered risk factors for 720 U/l), and an increased creatinine (1.4 mg/dl). NMS was considered and on day +11, droperidol and prochlorperazthe development of NMS. 6, 8 Leptomeningeal sarcomatosis was documented in our first patient 4 months prior to transine were stopped. Within the next 48 h, her fever resolved and mental status normalized, with CPK and creatinine plant and he received whole brain irradiation and intrathecal chemotherapy, although his CSF examination was negareturning to normal levels.
tive at the time of transplant. Conceivably, all these factors and their well recognized central nervous system effects and toxicities could have predisposed our patients to Discussion develop NMS. Exhaustion, dehydration, and other medical illnesses are frequently seen post-transplantation and could NMS usually develops within 4-5 days after receiving psyplay a role in the development of this acute syndrome. chotropic drugs, with 90% of cases developing within 10
In summary, we present two patients with signs and days.
6 Our cases presented in this time frame, with the first symptoms of NMS after high-dose chemotherapy and an developing 48 h after beginning haloperidol, and the second autotransplant. Untreated NMS has a 20% mortality 6 but, within 4 days of beginning prochlorperazine and droperiif recognized early, can be self-limited if the causative drug dol. Resolution of NMS occurs in about a quarter of cases is stopped and bromocriptine and/or dantrolene are given within 48 h and about two-thirds within 1 week. 8 In our as needed. 6, 8 Since neuroleptic medications are frequently report, both patients improved dramatically during 1 week used in the transplant setting, it is important to recognize after stopping the drugs.
that the use of these medications in concert with the physiClinical and laboratory features of NMS are thought to ologic stress of transplant can result in this drug-related result from central and peripheral dopaminergic blockade complication. produced by neuroleptics. 6, 8 Posterior hypothalamic dopaminergic blockade modifies the body temperature 'set-point' disrupting thermoregulatory mechanisms and the ability to
